NovoCure Ltd.
Clinical trials sponsored by NovoCure Ltd., explained in plain language.
A medical device company developing tumor-treating electric fields for cancer therapy.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Electric field therapy combined with chemo shows promise for tough pancreatic cancer
Disease control CompletedThis pilot study tested a wearable device that delivers low-intensity electric fields (TTFields) together with immunotherapy (atezolizumab) and two chemotherapy drugs (gemcitabine and nab-paclitaxel) in 84 people with metastatic pancreatic cancer who had not received prior treatm…
Phase 2 • Sponsor: NovoCure Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Electric field therapy plus standard treatment shows promise for deadly brain cancer
Disease control CompletedThis study tested a device called Optune, which delivers electric fields to the brain, alongside radiation and chemotherapy for people newly diagnosed with glioblastoma, an aggressive brain cancer. About 981 adults took part. The goal was to see if adding Optune to standard treat…
Sponsor: NovoCure Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Electric field device shows promise in tough pancreatic cancer trial
Disease control CompletedThis phase 3 trial tested a wearable device called Tumor Treating Fields (TTFields) combined with standard chemotherapy for people with locally advanced pancreatic cancer that cannot be removed by surgery. The device sends low-intensity electric fields to the tumor area to disrup…
Phase 3 • Sponsor: NovoCure Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC